Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Revenue (2016 - 2025)

Historic Revenue for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $264.0 million.

  • Arrowhead Pharmaceuticals' Revenue rose 1046132.0% to $264.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.1 billion, marking a year-over-year increase of 4353924.0%. This contributed to the annual value of $829.4 million for FY2025, which is 2325815.26% up from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Revenue of $264.0 million as of Q4 2025, which was up 1046132.0% from $256.5 million recorded in Q3 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Revenue ranged from a high of $542.7 million in Q1 2025 and a low of $2.5 million during Q4 2024
  • For the 5-year period, Arrowhead Pharmaceuticals' Revenue averaged around $99.9 million, with its median value being $32.8 million (2021).
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Revenue crashed by 9432.26% in 2023, and later soared by 1046132.0% in 2025.
  • Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' Revenue stood at $27.4 million in 2021, then surged by 127.95% to $62.5 million in 2022, then plummeted by 94.32% to $3.6 million in 2023, then dropped by 29.6% to $2.5 million in 2024, then surged by 10461.32% to $264.0 million in 2025.
  • Its last three reported values are $264.0 million in Q4 2025, $256.5 million for Q3 2025, and $27.8 million during Q2 2025.